Downregulation of IL-8, ECP, and total IgE in the tears of patients with atopic keratoconjunctivitis treated with rebamipide eyedrops

Clinical and Translational Allergy

Shigeru Kinoshita³  Chie Sotozono³  Jun Shoji¹  Mayumi Ueta² 

[1] Division of Ophthalmology, Department of Visual Sciences, Nihon University School of Medicine, Tokyo, Japan;Faculty of Life and Medical Sciences, Doshisha University, Kyotanabe, Japan;Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan

关键词: Dry eye;    Total IgE;    ECP;    IL-8;    Tears;    Atopic keratoconjunctivitis (AKC);    Rebamipide;   

Others  :  1092748
DOI  :  10.1186/2045-7022-4-40

 received in 2014-06-17, accepted in 2014-10-13,  发布年份 2014

【 摘 要 】

Rebamipide eyedrops are approved in Japan for the treatment of dry eye disease. Some patients with allergic conjunctival diseases also manifest dry eye. Earlier we reported that rebamipide suppressed polyI:C-induced inflammatory cytokines in human conjunctival epithelial cells. In the current study we examined the effect of rebamipide eyedrops on the level of interleukin-8 (IL-8), eosinophil cationic protein (ECP), and total IgE on the ocular surface.

We prescribed rebamipide eyedrops to patients with atopic keratoconjunctivitis (AKC) who presented with dry eye (6 eyes in 4 AKC patients) and measured the IL-8, ECP, and total IgE levels in their tears before- and 2, and 4–6 weeks after the start of rebamipide treatment. To measure the IL-8 and total IgE levels in their tears we used BD™ CBA Flex sets; ECP measurements were with ELISA. The level of IL-8, ECP, and total IgE in the tears of AKC patients was reduced significantly 4–6 weeks after the start of rebamipide treatment. We also recorded subjective symptoms associated with AKC, e.g. itching, foreign body sensation, and eye mucus discharge, by using a patient questionnaire. Their subjective symptoms associated with AKC were also significantly ameliorated at 2 and 4–6 weeks.

Our observations suggest that the anti-inflammatory effects of rebamipide eyedrops help to combat human ocular surface inflammation and that they may be a new effective therapy in patients with AKC.

【 授权许可】

   
2014 Ueta et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Iijima K, Ichikawa T, Okada S, Ogawa M, Koike T, Ohara S, Shimosegawa T: Rebamipide, a cytoprotective drug, increases gastric mucus secretion in human: evaluations with endoscopic gastrin test. Dig Dis Sci 2009, 54:1500-1507.
• [2]Ishihara K, Komuro Y, Nishiyama N, Yamasaki K, Hotta K: Effect of rebamipide on mucus secretion by endogenous prostaglandin-independent mechanism in rat gastric mucosa. Arzneimittelforschung 1992, 42:1462-1466.
• [3]Murakami K, Okajima K, Uchiba M, Harada N, Johno M, Okabe H, Takatsuki K: Rebamipide attenuates indomethacin-induced gastric mucosal lesion formation by inhibiting activation of leukocytes in rats. Dig Dis Sci 1997, 42:319-325.
• [4]Yoshida N, Yoshikawa T, Iinuma S, Arai M, Takenaka S, Sakamoto K, Miyajima T, Nakamura Y, Yagi N, Naito Y, Mukai F, Kondo M: Rebamipide protects against activation of neutrophils by Helicobacter pylori. Dig Dis Sci 1996, 41:1139-1144.
• [5]Urashima H, Takeji Y, Okamoto T, Fujisawa S, Shinohara H: Rebamipide increases mucin-like substance contents and periodic acid schiff reagent-positive cells density in normal rabbits. J Ocul Pharmacol Ther 2012, 28:264-270.
• [6]Kinoshita S, Awamura S, Nakamichi N, Suzuki H, Oshiden K, Yokoi N: A multicenter, open-label, 52-week study of 2% rebamipide (OPC-12759) ophthalmic suspension in patients with dry eye. Am J Ophthalmol 2014, 157:576-583 e571.
• [7]Kinoshita S, Awamura S, Oshiden K, Nakamichi N, Suzuki H, Yokoi N: Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study. Ophthalmology 2012, 119:2471-2478.
• [8]Kinoshita S, Oshiden K, Awamura S, Suzuki H, Nakamichi N, Yokoi N: A randomized, multicenter phase 3 study comparing 2% rebamipide (OPC-12759) with 0.1% sodium hyaluronate in the treatment of dry eye. Ophthalmology 2013, 120:1158-1165.
• [9]Suzuki S, Goto E, Dogru M, Asano-Kato N, Matsumoto Y, Hara Y, Fujishima H, Tsubota K: Tear film lipid layer alterations in allergic conjunctivitis. Cornea 2006, 25:277-280.
• [10]Toda I, Shimazaki J, Tsubota K: Dry eye with only decreased tear break-up time is sometimes associated with allergic conjunctivitis. Ophthalmology 1995, 102:302-309.
• [11]Ueta M, Sotozono C, Yokoi N, Kinoshita S: Rebamipide suppresses PolyI:C-stimulated cytokine production in human conjunctival epithelial cells. J Ocul Pharmacol Ther 2013, 29:688-693.
• [12]Ueta M, Sotozono C, Koga A, Yokoi N, Kinoshita S: Usefulness of a new therapy using rebamipide eyedrops in patients with VKC/AKC refractory to conventional anti-allergic treatments. Allergol Int 2014, 63:75-81.
• [13]Shoji J, Kitazawa M, Inada N, Sawa M, Ono T, Kawamura M, Kato H: Efficacy of tear eosinophil cationic protein level measurement using filter paper for diagnosing allergic conjunctival disorders. Jpn J Ophthalmol 2003, 47:64-68.